{"id":"W4200255107","doi":"10.1200/jco.21.00931","title":"Single-Agent Mosunetuzumab Shows Durable Complete Responses in Patients With Relapsed or Refractory B-Cell Lymphomas: Phase I Dose-Escalation Study","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Monoclonal and Polyclonal Antibodies Research","field":"Medicine","cited_by":290,"is_retracted":false,"has_abstract":true,"ca_institutions":"Roche (Canada); Spinal Cord Injury BC; University of British Columbia; McGill University; Jewish General Hospital","funders":"Cilag; Genentech; MorphoSys; Yuhan; BeiGene; Bristol-Myers Squibb; Constellation Pharmaceuticals; Pharmacyclics; Agios Pharmaceuticals; Karyopharm Therapeutics; MEI Pharma; Sunesis; Juno Therapeutics; Celltrion; Adaptive Biotechnologies; Loxo Oncology; Astex Pharmaceuticals; H. Lundbeck A/S; TG Therapeutics; Pfizer; Incyte; F. Hoffmann-La Roche; University of Pennsylvania; Janssen Biotech; Teva Pharmaceutical Industries; Unum Therapeutics; Daiichi Sankyo Europe; National Cancer Institute; Servier; Calithera Biosciences; Gilead Sciences; GlaxoSmithKline; Amgen; LAM Therapeutics; Alimera Sciences; Celgene; AstraZeneca; Eli Lilly and Company","keywords":"Refractory (planetary science); Safety profile; Phases of clinical research; Clinical trial; Cancer; Stage (stratigraphy); Maximum tolerated dose","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00111877,0.0008133561,0.001593485,0.0002837454,0.0002553288,0.000586924,0.0004839048,0.0005576884,0.001733633],"category_scores_gemma":[0.000508297,0.0002953474,0.0006549772,0.0002750205,0.000315938,0.0003971769,0.0002013807,0.001722731,0.0005262658],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005889579,"about_ca_system_score_gemma":0.0006292465,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004101969,"about_ca_topic_score_gemma":0.001039725,"domain_scores_codex":[0.9996866,0.0001156771,0.00002351334,0.00005839979,0.00005075459,0.00006504209],"domain_scores_gemma":[0.9996219,0.00005912337,0.00008656855,0.00004565538,0.00002534976,0.0001614173],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.2868516,0.09182177,0.01893226,0.001580876,0.002997935,0.0006662601,0.0007930974,0.004687247,0.2605634,0.0002517176,0.006401279,0.3244525],"study_design_scores_gemma":[0.2893409,0.6115185,0.06520068,0.0000815695,0.001004003,0.001269946,0.00009875691,0.003700076,0.0213199,0.0002255346,0.00617967,0.00006047814],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9966059,0.001628875,0.0003764576,0.00008786128,0.00002163138,0.0004611324,0.0002410074,0.00005614012,0.0005210618],"genre_scores_gemma":[0.9962657,0.0008944834,0.0007851541,0.0002454596,0.00005200523,0.0004114915,0.0007087277,0.00001512329,0.0006217972],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001733633,"threshold_uncertainty_score":0.005916655,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1932406315214324,"score_gpt":0.4643134210697562,"score_spread":0.2710727895483238,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}